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Beau M. Hawkins, MDSEE PAGE 259I n contrast to coronary artery disease in which arobust collection of data has demonstratedthe merits of percutaneous revascularization,
research investigating peripheral vascular interven-
tion (PVI) has not yet matured in terms of magnitude,
quality, or clarity. For example, only 1 randomized
trial has assessed the efﬁcacy of PVI relative to surgi-
cal bypass in patients with critical limb ischemia
(CLI). That study was published more than 1 decade
ago, and it examined what is now considered to be a
rudimentary endovascular technique (e.g., balloon
angioplasty [PTA]) (1).
Many technologies such as drug-coated balloons,
drug-eluting stents (DES), and atherectomy devices
have been developed in recent years to treat periph-
eral artery disease (PAD). However, randomized trials
comparing the performance of these novel in-
novations against each other are largely lacking, and
the PVI published data has become inundated with
small observational data sets of suboptimal scientiﬁc
value. Moreover, procedural success rates for PVI are
exceptional, even in the most complex lesion subsets,
but technical success and even long-term vessel
patency do not always translate into meaningful
clinical beneﬁts for patients (2). As such, the lingering
dilemma for clinicians performing PVI is no longer
“can I open this artery?” but rather “how should I treat
this artery and how will I deﬁne success?” Answers to
the latter, the Achilles heel of PVI, remain unclear.
Within this framework, in this issue of JACC: Car-
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vant to the contents of this paper to disclose.1-year wound healing and quality-of-life outcomes
from the ACHILLES (Comparison of angioplasty and
DES in the treatment of subjects With ischemicinfrapopliteal arterial disease) trial. ACHILLES was
a randomized study of 200 patients comparing
balloon-expandable sirolimus-eluting stents (SES)
with PTA for patients with infrapopliteal PAD. The
primary analysis was previously published and
demonstrated that SES use resulted in lower restenosis
rates and improved vessel patency at 1 year (2).
In the present ACHILLES analysis, wound healing
was assessed in 78 patients with 109 wounds, with
roughly equal numbers of patients receiving SES and
PTA (3). No differences were present in rates of
wound closure or absolute wound reduction between
the SES and PTA arms. The percentage of wound
volume reduction was signiﬁcantly better at 6 months
in the SES group (95% vs. 60% volume reduction,
p ¼ 0.048), but this difference was no longer signiﬁ-
cant at 1 year due to “catch up” in the PTA group.
Health-related quality-of-life (HRQOL) was as-
sessed in the entire ACHILLES cohort and wound
subgroup using a validated questionnaire. HRQOL
metrics improved in both SES and PTA groups at 1 year,
but the change was statistically signiﬁcant in only the
SES arm. There was a trend toward more gain in
quality-adjusted life-years in the SES group as well.
Similar ﬁndings were present in the wound subgroup.
This ACHILLES analysis undoubtedly represents
some progress for PVI research. Other randomized
studies have investigated DES use in the infrapopli-
teal circulation. In general, these trials demonstrated
improvements in patency and various clinical end-
points with DES use, but none have speciﬁcally
examined wound healing or patient-reported HRQOL
metrics (4,5). The authors are to be commended
for providing data from a randomized PAD trial
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269that examines whether drug-elution technologies
can affect these important endpoints. Such ﬁndings
are novel and represent a unique inclusion of patient-
centric outcomes with traditional PAD trial endpoints
such as restenosis, patency, and target vessel revas-
cularization. On the basis of the ﬁnding of greater
wound volume reduction in the SES arm at 6 months,
the authors suggest that SES may accelerate wound
healing. This assertion, if true, is particularly relevant
because delayed wound healing may increase infec-
tion risk, adversely affect quality of life, and increase
health care costs (6–8).
Despite these attributes, the principal ﬁndings of
this analysis do have some limitations. Despite better
patency and restenosis rates, the use of SES for
infrapopliteal disease did not improve wound closure
rates or wound healing at 1 year. If SES accelerate
wound healing as the authors suggest, it remains
unclear why similar rates of amputation and target
vessel revascularization were noted. Moreover,
although the improvement in HRQOL was signiﬁcant
only in the SES group, the baseline score in the PTA
arm was objectively much higher, and this may have
minimized the ability to identify a similar, statisti-
cally signiﬁcant improvement in the PTA arm.
Indeed, the 12-month HRQOL scores appeared quali-
tatively similar between the SES and PTA groups, and
there was no incremental improvement in quality-
adjusted life-years using SES compared with PTA. It
is also difﬁcult to ascertain whether the statistically
signiﬁcant changes in HRQOL reported represent any
clinical impact because signiﬁcant p values in HRQOL
studies may not always correlate with patient beneﬁt.
Finally, mean lesion lengths were 2.6 cm and 3.2 cm
in the SES and PTA groups, respectively. Most tibial
disease encountered in clinical practice, particularly
that in a critical limb population, is long, calciﬁed,
and multivessel in nature. As such, the widespread
adoption of DES with existing technologies for tibial
disease may be impractical.
In addition, the achievement of wound closure in
patients with CLI relies on much more than estab-
lishing in-line ﬂow to the foot. Emerging data
suggest that limb salvage and wound healing rates
may be better when using an angiosome-basedrevascularization strategy, whereby the tibial artery
supplying the area of tissue loss is treated to restore
direct perfusion (9). Medical treatment is also
extremely important; for example, statin use before
revascularization has been shown to be associated
with improved limb salvage rates (10). Aggressive
wound care, as part of a coordinated limb preserva-
tion program, can also impact wound healing. The
current ACHILLES trial analysis did not account for
angiosome-guided revascularization, and details on
medication and wound care algorithms are not
available.
In light of these considerations, what constitutes
success with lower extremity revascularization? This
is a complicated question that involves examining
endpoints relevant to both clinicians and patients.
Trials must include homogeneous populations when
possible, as the treatment endpoints for claudicants
may be far different from those with CLI (11). Addi-
tionally, standardized endpoints and deﬁnitions must
be used so that accurate inferences can be made across
different studies. Validation of patient-reported
outcome measures will be needed to understand the
magnitude of impact that a novel technology offers.
Finally, sophisticated cost analyses will be needed to
determine how to optimize treatment value for pa-
tients with PAD. With these reﬁnements incorporated
into a future prospective trial design and with the
maturation of existing registries, many lingering
questions will start to have answers, and many pa-
tients with PAD will begin reaping the beneﬁts.
In the end, although the ACHILLES trial has
demonstrated beneﬁts in terms of restenosis and
patency with SES use in infrapopliteal arteries, it re-
mains unclear whether this translates into meaning-
ful clinical beneﬁt for patients. PVI research is moving
in the right direction by beginning to focus on the
right questions, but there is obviously much more to
be learned.
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